Your browser doesn't support javascript.
loading
Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations.
Wilczynski, Ophélie; Boisbouvier, Anthony; Radoszycki, Lise; Cotté, François-Emery; Gaudin, Anne-Françoise; Lemasson, Hervé.
Afiliação
  • Wilczynski O; Carenity, Paris, France.
  • Boisbouvier A; Carenity, Paris, France.
  • Radoszycki L; Carenity, Paris, France.
  • Cotté FE; Bristol-Myers Squibb France, Rueil-Malmaison, France.
  • Gaudin AF; Bristol-Myers Squibb France, Rueil-Malmaison, France.
  • Lemasson H; Bristol-Myers Squibb France, Rueil-Malmaison, France.
J Med Internet Res ; 24(1): e25792, 2022 01 11.
Article em En | MEDLINE | ID: mdl-35014969
ABSTRACT

BACKGROUND:

New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented.

OBJECTIVE:

This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management.

METHODS:

This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed.

RESULTS:

Of 82 patients included (mean age 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient's initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss.

CONCLUSIONS:

With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clínicos Gerais / Neoplasias Pulmonares Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clínicos Gerais / Neoplasias Pulmonares Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article